Silencing Tspan1 inhibits migration and invasion, and induces the apoptosis of human pancreatic cancer cells

Tian,Jiaxun; Zhang,Rui; Piao,Haiyan; Li,Xiaoxi; Sheng,Weiwei; Zhou,Jianping; Dong,Ming; Zhang,Xiaobo; Yan,Xiaofei; Shang,Wen; Zhao,Jianfeng; Xu,Lan; Liu,Fang; Shi,Gang

doi:10.3892/mmr.2018.9331

Silencing Tspan1 inhibits migration and invasion, and induces the apoptosis of human pancreatic cancer cells

Authors:
- Jiaxun Tian
- Rui Zhang
- Haiyan Piao
- Xiaoxi Li
- Weiwei Sheng
- Jianping Zhou
- Ming Dong
- Xiaobo Zhang
- Xiaofei Yan
- Wen Shang
- Jianfeng Zhao
- Lan Xu
- Fang Liu
- Gang Shi
View Affiliations

Affiliations: Department of Laboratory, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China, Department of Colorectal Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China, Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042, P.R. China, Gastrointestinal Surgery Department, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, General Surgery Department, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: July 27, 2018 https://doi.org/10.3892/mmr.2018.9331
Pages: 3280-3288
Copyright: © Tian et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer (PCC) is one of the most dangerous types of tumor as it is very difficult to treat and its 5‑year survival rate is <6%. To date, there have been no effective therapeutic strategies to treat PCC, thus, novel effective therapeutic methods are required. Tetraspanin 1 (Tspan1) is a novel member of the tetraspanins superfamily and is highly expressed in a variety of types of cancer, including gastric, hepatocellular and colonic carcinomas. However, the detailed functional role of Tspan1 in pancreatic cancer cells is still unclear and further investigation is required to uncover its therapeutic potential for the treatment of different tumor types. The purpose of the present study was to investigate the expression of Tspan1 in human PCC tissues and cells, and explore the effect of Tspan1 silencing on invasion, migration, cell survival and apoptosis in human PCC to clarify its function. Expression levels of Tspan1 were analyzed in human pancreatic cancer tissues and the cell lines Capan‑2 and SW1990 using immunohistochemistry staining, reverse transcription‑quantitative polymerase chain reaction and western blotting. The effects of downregulation of Tspan1 expression on cell survival, apoptosis, invasion and migration were investigated viaTspan1‑small interfering (si)RNA transfection into human PCC cell lines. The results indicated that Tspan1 expression was increased in human PCC tissues compared with the adjacent normal pancreatic tissues. Tspan1 was highly expressed in the human PCC cell lines Capan‑2 and SW1990 when compared with the normal pancreatic cell line HPC‑Y5. In addition, transfection with siRNA‑targeting Tspan1 significantly reduced cell migration and invasion, and increased the cell apoptosis of Capan‑2 and SW1990. The present findings highlighted the important role of Tspan1 in human PCC cell migration, invasion and apoptosis. Thus, Tspan1 RNA interference may serve as a potential therapeutic strategy to treat human PCC.

View Figures

View References

1	Vincent A, Herman J, Schuick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Bosetti C, Bertuccio P, Negri E, La Vecchia C, Zeegers MP and Boffetta P: Pancreatic cancer: Overview of descriptive epidemiology. Mol Carcinog. 51:3–13. 2012. View Article : Google Scholar : PubMed/NCBI
4	Loos M, Kleeff J, Friess H and Büchler MW: Surgical treatment of pancreatic cancer. Ann NY Acad Sci. 1138:169–180. 2008. View Article : Google Scholar : PubMed/NCBI
5	Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E, Barni S, Di Costanzo F, Dapretto E, Tonini G, et al: Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: A randomised, multicentre, phase II trial. Lancet Oncol. 9:39–44. 2008. View Article : Google Scholar : PubMed/NCBI
6	Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Toda N, Kogure H, Matsubara S, Ito Y, Togawa O, et al: A multicentrer and omised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br J Cancer. 106:1934–1939. 2012. View Article : Google Scholar : PubMed/NCBI
7	Tuinmann G, Hegewisch-Becker S, Zschaber R, Kehr A, Schulz J and Hossfeld DK: Gemcitabine and mitomycin C in advanced pancreatic cancer: A single-institution experience. Anticancer Drugs. 15:575–579. 2004. View Article : Google Scholar : PubMed/NCBI
8	Hall WA, Colbert LE, Nickleach D, Switchenko J, Liu Y, Gillespie T, Lipscomb J, Hardy C, Kooby DA, Prabhu RS, et al: The influence of radiation therapy dose escalation on overall survival in unresectable pancreatic adenocarcinoma. J Gastrointest Oncol. 5:77–85. 2014.PubMed/NCBI
9	Veenbergen S and Van Spriel AB: Tetraspanins in the immune response against cancer. Immunol Lett. 138:129–136. 2011. View Article : Google Scholar : PubMed/NCBI
10	Berditchevski F, Odintsova E, Sawada S and Gilber E: Expression of the palmitoylation-deficient CD151 weakens the association of alpha 3 beta 1 integrin with the tetraspanin-enriched microdomains and affects integrin dependent signaling. J Biol Chem. 277:36991–37000. 2002. View Article : Google Scholar : PubMed/NCBI
11	Levy S and Shoham T: The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol. 5:136–148. 2005. View Article : Google Scholar : PubMed/NCBI
12	Pedro AL: Functional implications of tetraspanin proteins in cancer biology. Cancer Sci. 98:1666–1677. 2007. View Article : Google Scholar : PubMed/NCBI
13	Serru V, Dessen P, Boucheix C and Rubinstein E: Sequence and expression of seven new tetraspans. Biochim Biophys Acta. 1478:159–163. 2000. View Article : Google Scholar : PubMed/NCBI
14	Scholz CJ, Kurzeder C, Koretz K, Windisch J, Kreienberg R, Sauer G and Deissler H: Tspan-1 is a tetraspanin preferentially expressed by mucinous and endometrioid subtypes of human ovarian carcinomas. Cancer Lett. 275:198–203. 2009. View Article : Google Scholar : PubMed/NCBI
15	Chen L, Zhu YY, Zhang XJ, Wang GL, Li XY, He S, Zhang JB and Zhu JW: TSPAN1 protein expression: A significant prognostic indicator for patients with colorectal adenocarcinoma. World J Gastroenterol. 15:2270–2276. 2009. View Article : Google Scholar : PubMed/NCBI
16	Chen L, Yuan D, Wang GL, Wang Y, Wu YY and Zhu J: Clinicopathological significance of expression of Tspan-1, Jab1 and p27 in human hepatocellular carcinoma. J Korean Med Sci. 25:1438–1442. 2010. View Article : Google Scholar : PubMed/NCBI
17	Chen L, Li X, Wang GL, Wang Y, Zhu YY and Zhu J: Clinicopathological significance of overexpression of TSPAN1, Ki67 and CD34 in gastric carcinoma. Tumori. 94:531–538. 2008. View Article : Google Scholar : PubMed/NCBI
18	Wollscheid V, Kühne-Heid R, Stein I, Jansen L, Köllner S, Schneider A and Dürst M: Identification of a new proliferation associated protein NET-1/C4.8 characteristic for a subset of high-grade cervical intraepithelial neoplasia and cervical carcinomas. Int J Cancer. 99:771–775. 2002. View Article : Google Scholar : PubMed/NCBI
19	Xu J, Stolk JA, Zhang X, Silva SJ, Houghton RL, Matsumura M, Vedvick TS, Leslie KB, Badaro R and Reed SG: Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 60:1677–1682. 2000.PubMed/NCBI
20	Liu L, He B, Liu WM, Zhou D, Cox JV and Zhang XA: Tetraspanin CD151 promotes cell migration by regulating integrin trafficking. J Biol Chem. 282:31631–31642. 2007. View Article : Google Scholar : PubMed/NCBI
21	Yamamoto Y, Grubisic K and Oelgeschläger M: Xenopus tetraspanin-1 regulates gastrulation movements and neural differentiation in the early xenopus embryo. Differentiation. 75:235–245. 2007. View Article : Google Scholar : PubMed/NCBI
22	Chen L, Yuan D, Zhao R, Li H and Zhu J: Suppression of TSPAN1 by RNA interference inhibits proliferation and invasion of colon cancer cells in vitro. Tumori. 96:744–750. 2010. View Article : Google Scholar : PubMed/NCBI
23	Chen L, Zhu Y, Li H, Wang GL, Wu YY, Lu YX, Qin J, Tuo J, Wang JL and Zhu J: Knockdown of TSPAN1 by RNA silencing and antisense technique inhibits proliferation and infiltration of human skin squamous carcinoma cells. Tumori. 96:289–295. 2010. View Article : Google Scholar : PubMed/NCBI
24	Carlson RW, Hudis CA and Pritchard KI: Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: Evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw. 4:971–979. 2006. View Article : Google Scholar : PubMed/NCBI
25	Desouki MM, Liao S, Huang H, Conroy J, Nowak NJ, Shepherd L, Gaile DP and Geradts J: Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach. J Cancer Res Clin Oncol. 137:795–809. 2011. View Article : Google Scholar : PubMed/NCBI
26	Liu H, Ma Q and Li J: High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells. Mol Cell Biochem. 347:95–101. 2011. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data usingreal-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Albrethsen J, Bøgebo R, Gammeltoft S, Olsen J, Winther B and Raskov H: Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP1-3) in colon cancer serum and tumours: A biomarker study. BMC Cancer. 5:82005. View Article : Google Scholar : PubMed/NCBI
29	Fei Y, Wang J, Liu W, Zuo H, Qin J, Wang D, Zeng H and Liu Z: CD151 promotes cancer cell metastasis via integrins α3 β1 and α6 β1 in vitro. Mol Med Rep. 6:1226–1230. 2012. View Article : Google Scholar : PubMed/NCBI
30	Takahashi M, Sugiura T, Abe M, Ishii K and Shirasuna K: Regulation of c-Met signaling by the tetraspanin KAI-1/CD82 affects cancer cell migration. Int J Cancer. 121:1919–1929. 2007. View Article : Google Scholar : PubMed/NCBI
31	Hölters S, Anacker J, Jansen L, Beer-Grondke K, Dürst M and Rubio I: Tetraspanin 1 promotes invasiveness of cervical cancer cells. Int J Oncol. 43:503–512. 2013. View Article : Google Scholar : PubMed/NCBI
32	Lu Z, Luo T, Nie M, Pang T, Zhang X, Shen X, Ma L1, Bi J, Wei G, Fang G and Xue X: TSPAN1 functions as an oncogene in gastric cancer and is downregulated by miR-573. FEBS Lett. 589:1988–1994. 2015. View Article : Google Scholar : PubMed/NCBI
33	Wang H, Rana S, Giese N, Büchler MW and Zöller M: Tspan8, CD44v6 and alpha6beta4 are biomarkers of migrating pancreatic cancer-initiating cells. Int J Cancer. 133:416–426. 2013. View Article : Google Scholar : PubMed/NCBI
34	Schmelz M, Cress AE, Scott KM, Bürger F, Cui H, Sallam K, McDaniel KM, Dalkin BL and Nagle RB: Different phenotypes in human prostate cancer: Alpha6 or alpha3 integrin in cell-extra-cellular adhesion sites. Neoplasia. 4:243–254. 2002. View Article : Google Scholar : PubMed/NCBI
35	Herlevsen M, Schmidt DS, Miyazaki K and Zöller M: The association of the tetraspanin D6.1A with the alpha6beta4 integrin supports cell motility and liver metastasis formation. J Cell Sci. 116:4373–4390. 2003. View Article : Google Scholar : PubMed/NCBI
36	Chen Z, Mustafa T, Trojanowicz B, Brauckhoff M, Gimm O, Schmutzler C, Köhrle J, Holzhausen HJ, Kehlen A, Klonisch T, et al: CD82, and CD63 in thyroid cancer. Int J Mol Med. 14:517–527. 2004.PubMed/NCBI